auto_awesome
Want to know who else bid on this?
Proposal Forge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Department
National Research Council CanadaAmount
$10.0M
Province
ABType
Contribution
Agreement Number
172-2022-2023-Q3-998413
Purpose
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
Providence Therapeutics Holdings Inc. × National Research Council Canada
8 grants totalling $48.7M
Industrial Research Assistance Program – Contributions to Firms
1,000 grants totalling $122.3M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |